Theralase Launches First Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
WellCare to Pilot National At-Home COVID-19 Testing Program for Medicare Advantage Members yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
(1)
DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Miscellaneous
Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
19.01.2021 / 15:00
Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals LNAplus
TM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids
Secarna s partner Lipigon has selected an LNAplus
TM ASO candidate targeting ANGPTL4, called
Lipisense, which has shown unique efficacy in reducing lipid triglycerides in experimental disease models and is now entering pre-clinical safety development
High levels of plasma lipids triglycerides are associated with a plethora of lipid-related diseases with yet unmet clinical treatment needs
Ortho Clinical Diagnostics Announces Launch of Initial Public Offering
RARITAN, N.J., Jan. 19, 2021 /PRNewswire/ Ortho Clinical Diagnostics Holdings plc ( Ortho ), the world s largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the launch of its initial public offering of its ordinary shares. Ortho is offering 70 million ordinary shares, with the initial public offering price expected to be between $20.00 and $23.00 per share.
Ortho expects to grant the underwriters a 30-day option to purchase up to 10.5 million additional ordinary shares at the initial public offering price less underwriting discounts and commissions. Ortho has applied to have its ordinary shares approved for listing on The NASDAQ Stock Market under the symbol OCDX.